Q3 Earnings Estimate for Quanterix Issued By Leerink Partnrs

Quanterix Co. (NASDAQ:QTRX) – Equities researchers at Leerink Partnrs lifted their Q3 2024 earnings per share (EPS) estimates for Quanterix in a note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.19) per share for the quarter, up from their prior estimate of ($0.20). The consensus estimate for Quanterix’s current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Quanterix’s Q4 2024 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS and Q4 2025 earnings at ($0.21) EPS.

Other analysts also recently issued reports about the company. Scotiabank cut their price objective on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating for the company in a research report on Monday, August 12th. TD Cowen increased their target price on shares of Quanterix from $13.50 to $16.00 and gave the stock a “hold” rating in a research note on Wednesday.

Quanterix Stock Down 4.0 %

QTRX stock opened at $11.44 on Friday. Quanterix has a 52-week low of $10.50 and a 52-week high of $29.70. The business has a fifty day moving average of $12.95 and a two-hundred day moving average of $13.96. The stock has a market cap of $439.07 million, a price-to-earnings ratio of -10.90 and a beta of 1.36.

Insider Buying and Selling at Quanterix

In other news, Director David R. Walt acquired 47,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was acquired at an average cost of $13.29 per share, with a total value of $624,630.00. Following the transaction, the director now owns 1,487,342 shares in the company, valued at approximately $19,766,775.18. This trade represents a 3.26 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Quanterix

Hedge funds have recently added to or reduced their stakes in the stock. Harbor Capital Advisors Inc. lifted its holdings in shares of Quanterix by 772.3% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 83,941 shares of the company’s stock valued at $1,109,000 after purchasing an additional 74,318 shares during the last quarter. Emerald Advisers LLC boosted its holdings in shares of Quanterix by 5.6% in the third quarter. Emerald Advisers LLC now owns 719,217 shares of the company’s stock valued at $9,321,000 after acquiring an additional 38,230 shares during the period. Easterly Investment Partners LLC grew its position in shares of Quanterix by 779.9% during the second quarter. Easterly Investment Partners LLC now owns 692,746 shares of the company’s stock worth $9,151,000 after acquiring an additional 614,012 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Quanterix in the 2nd quarter valued at $3,389,000. Finally, Picton Mahoney Asset Management increased its holdings in shares of Quanterix by 91.7% in the 2nd quarter. Picton Mahoney Asset Management now owns 165,076 shares of the company’s stock valued at $2,180,000 after acquiring an additional 78,984 shares during the period. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.